All Posts By

admin

Apr 02
0

Genetic Toxicologist Vacancy at AstraZeneca – Deadline Extended!

By | Uncategorized | No Comments

Do you have a primary focus on toxicology science with a working knowledge and experience of drug development?

An exciting opportunity exists to join the Genetic Toxicology Team in Cambridge to support the development of innovative drugs and improve patients’ lives.

The group is part of Functional and Mechanistic Safety, which is a global department that is part of the Clinical Pharmacology and Safety Sciences (CPSS) function & applies innovative science to drive the design, selection and development of safer medicines. The Functional and Mechanistic Safety group work collaboratively delivering safety science from early discovery through clinical development.

For more information and to apply, click here.

Job Reference: R-075502

Closing date: 16th April 2020

Mar 24
0

Duplex Sequencing Webinar

By | Webinar | No Comments

Working from home? Keep up to date with the latest sequencing technology for mutation detection by joining a webinar on Thursday March 26th on Duplex Sequencing. To register, click here.

Title: Duplex Sequencing™ Technology: Transforming Safety Testing

Date: Thursday, March 26, 2020

Time: 11:00 AM Eastern Daylight Time

Duration: 1 hour

Speakers:

Bob Young, MS
Program Consultant and Study Director, In Vivo Mutation
Merck KGaA, Darmstadt, Germany

Jesse Salk, MD, PhD
CEL, CSO and Founder
TwinStrand Biosciences

In this webinar, you will learn about:

  • Duplex Sequencing™ technology unmatched sensitivity and accuracy in NGS applications
  • Duplex technology applications in identification of carcinogenic chemicals
  • Global efforts to evaluate and adopt Duplex Sequencing™ technology for regulatory submission
  • Applications in drug and chemical safety assessment

Detailed description:

Duplex Sequencing™ technology is a new error-corrected NGS method that improves sequencing accuracy 100,000-fold. This increase in accuracy opens the door to significant reductions in time spent in drug development, allowing measurement of a compound’s carcinogenic risk months or even years earlier than current methods. DS technology now permits early measurement of ultra-rare new mutants. We will discuss the technology, clinical applications and then explore nonclinical safety assessment applications. Mouse and rat mutation data will be presented from various mutagens, tissues and genes. Mutant frequency data and mutational “fingerprint” data will be discussed in context of human tumors. Plans for collaborative qualification through the HESI Genetic Toxicology Technical Committee will be discussed.

Feb 27
0

Job vacancy at AstraZeneca – Genetic Toxicologist

By | Job advert | No Comments

Do you have a primary focus on toxicology science with a working knowledge and experience of drug development?

An exciting opportunity exists to join the Genetic Toxicology Team in Cambridge to support the development of innovative drugs and improve patients’ lives.

The group is part of Functional and Mechanistic Safety, which is a global department that is part of the Clinical Pharmacology and Safety Sciences (CPSS) function & applies innovative science to drive the design, selection and development of safer medicines. The Functional and Mechanistic Safety group work collaboratively delivering safety science from early discovery through clinical development.

For more information and to apply, click here.

Job Reference: R-075545

Closing date: 24th March 2020

 

Jan 24
0

EEMGS Abstract Deadline – Jan 31st

By | Meetings | No Comments

Mark your presence on the 48th European Environmental Mutagenesis and Genomics Society Annual Meeting (EEMGS2020) to be held in Porto, Portugal, between 6 – 8 May 2020, by submitting your abstract now!

There are only a few days left until the deadline of 31st January 2020. Do not miss out the opportunity to share your work with peers from industry, universities and regulatory bodies from all around the world. Submit your abstract here: https://www.eemgs2020.eu/en/registration/submissions/

The general theme of the congress is “Exposure and Susceptibility: bridging gaps to improve health”. The preliminary Scientific Programme is now available on their website: www.eemgs2020.eu

Jan 17
0

Gentronix Job Vacancy: In vitro mammalian gene mutation Study Director

By | Job advert | No Comments

Job vacancy at Gentronix for an in vitro mammalian gene mutation Study Director

Job Reference: GTXHPRT2020 

Opening Date – 10th January 2020
Closing Date – 10th February 2020

Gentronix is seeking an enthusiastic and highly motivated scientist to join our in vitro genetic toxicology team as an in vitro mammalian gene mutation Study Director. The team is growing due to planned services expansion and needs a committed and organised individual to help drive the expansion of the in vitro genetic toxicology service offering. The role will require good integration into the existing team and close working with the other Study Directors. For the successful applicant, the role presents opportunities to build-on and further develop their skills as a toxicologist within a CRO environment, with scope for further career progression within a growing and successful business.

For full job specifications and how to apply, click here.

Nov 11
0

Call for IGG Ordinary Committee Member

By | Uncategorized | No Comments

A position is available for an ordinary committee member of the Industrial Genotoxicity Group (IGG).  Committee members will be involved in setup of IGG meetings and also initiatives that of benefit to our members.

If you are interested in joining the committee, or have any questions, please contact Paul Rawlinson, the IGG Committee secretary (paul.rawlinson@gentronix.co.uk).

The deadline for putting yourself forward is the end of November.

Nov 11
0

HESI GTTC Comet Assay Survey

By | Uncategorized | No Comments

The Health and Environmental Sciences Institute Genetic Toxicology Technical Committee (HESI GTTC) needs your help.  We are developing a project to improve the clarity and application of OECD TG 489 (In Vivo Mammalian Alkaline Comet) for applications across most industries.  But to accomplish this, we need to identify the most critical issues and concerns to address.  So included below is a link for our survey that will help us gather this information.  If you have been considering, conducting, requesting, reviewing , or even avoiding regulated in vivo comet assay studies, please complete our survey.  And if you have any colleagues that may be willing to contribute their input, we would really appreciate it if you could forward to them the link for our survey. Regardless of one’s industry or level of experience with the comet assay, everyone’s input is very critical to this process.  The survey will only take a few minutes and we are asking participants to please complete it by the end of December 2019.  Please note that every participant will be informed of the results of this survey and the GTTC plans to address the issues raised.

HESI GTTC Survey Link:  https://www.surveymonkey.com/r/L627CBM

Sep 25
0

Paper in Mutagenesis: Extended treatment with recovery improves results in the peripheral blood lymphocyte micronucleus assay

By | Journals | No Comments

EDITOR’S CHOICE

Inclusion of an extended treatment with recovery improves the results for the human peripheral blood lymphocyte micronucleus assay

James Whitwell, Robert Smith, Teresa Chirom, Gary Watters, Victoria Hargreaves, Mel Lloyd, Sarah Phillips, Julie Clements

Mutagenesis, Volume 34, Issue 3, May 2019, Pages 217–237, https://doi.org/10.1093/mutage/gez011
Read the article here.
Aug 12
0

New Paper: Are All Bacterial Strains Required by OECD Needed?

By | Journals | No Comments

Are All Bacterial Strains Required by OECD Mutagenicity Test Guideline TG471 Needed?

Williams, Richard , DeMarini, David M. , et al Mutation Research/Genetic Toxicology and Environmental Mutagenesis August 2019

Read the latest paper in Mutation Research. Genetic Toxicology and Environmental Mutagenesis

Highlights

•Salmonella TA1535 detected few mutagens not detected by Salmonella TA100.
•Salmonella TA97 should be used in preference to Salmonella TA1537.
•Escherichia coli WP2 uvrA pKM101 is preferred to WP2 uvrA and Salmonella TA102.
•Salmonella TA98 & TA100 detected 93% of mutagens detected by all the TG471 strains.

DOI: 10.1016/j.mrgentox.2019.503081

Jul 08
0

ITTP PhD studentship with AstraZeneca and Imperial College, London

By | Studentships | No Comments

“Understanding the role of cohesin and the impact of structural variation on gene expression regulation in the 3D genome”

A fully funded ITTP PhD opportunity from the MRC, in conjunction with Imperial College, London and AstraZeneca, Cambridge to start September 2019.

See the full advert here.

Informal enquiries to Professor Nigel Gooderham (n.gooderham@imperial.ac.uk) or Dr Rhiannon David (rhiannon.david@astrazeneca.com).

Stipend: Current MRC rates plus an Imperial College/AstraZeneca supplement (4 years). Tuition fees paid. Start date Sept 2019.

Please send applications, including a CV and personal statement to: n.gooderham@imperial.ac.uk or rhiannon.david@astrazeneca.com

Deadline for applications 31st July 2019. 

Interviews to be held during August 2019 at AstraZeneca, Cambridge.